Our work in health economics, health policy and health statistics informs decision-making about health care and pharmaceutical issues at a global level.
of rare diseases have a single-gene cause
new drugs will be approved over the next 30 years
molecules with potential as tumour-agnostic therapies were in development in 2019
per QALY is the range for the cost effectiveness threshold used by NICE
decrease in new drugs coming to market is the estimate impact of U.S government price-setting
clinical trials supported the first digital therapeutic recommended by NICE
